Artivion, Inc. $AORT Shares Sold by Vanguard Group Inc.

Key Points

• The Vanguard Group Inc. reduced its holdings in Artivion, Inc. by 0.8%, owning 2,782,007 shares valued at approximately $68.38 million after selling 22,877 shares.
• Insider sales included SVP Jean F. Holloway and insider John E. Davis, who sold 10,000 and 10,802 shares respectively, indicating a decrease in their ownership by 5.49% and 4.92%.
• Artivion has received mixed analyst ratings, with a consensus rating of "Buy" and an average target price of $40.63, following upgrades and downgrades by various analysts.

Vanguard Group Inc. reduced its position in shares of Artivion, Inc. (NYSE:AORT - Free Report) by 0.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,782,007 shares of the company's stock after selling 22,877 shares during the quarter. Vanguard Group Inc. owned about 6.52% of Artivion worth $68,382,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in AORT. Illinois Municipal Retirement Fund increased its position in Artivion by 3.1% during the 1st quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock valued at $504,000 after purchasing an additional 611 shares during the period. MCF Advisors LLC boosted its stake in shares of Artivion by 109.3% during the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after purchasing an additional 614 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Artivion by 3.3% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,559 shares of the company's stock valued at $645,000 after buying an additional 727 shares during the period. Barclays PLC raised its stake in Artivion by 1.2% in the fourth quarter. Barclays PLC now owns 71,697 shares of the company's stock worth $2,051,000 after buying an additional 820 shares in the last quarter. Finally, Legacy Advisors LLC purchased a new stake in Artivion during the first quarter worth $28,000. 86.37% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. JMP Securities lifted their price target on Artivion from $33.00 to $42.00 and gave the company a "market outperform" rating in a report on Friday, August 8th. Canaccord Genuity Group lifted their target price on Artivion from $35.00 to $41.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Needham & Company LLC raised their price target on shares of Artivion from $45.00 to $50.00 and gave the company a "buy" rating in a report on Friday, August 22nd. Wall Street Zen raised shares of Artivion from a "hold" rating to a "buy" rating in a research report on Monday. Finally, Stifel Nicolaus increased their target price on shares of Artivion from $36.00 to $40.00 and gave the company a "buy" rating in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $40.63.

Insider Buying and Selling at Artivion

In other Artivion news, insider John E. Davis sold 10,802 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total value of $471,723.34. Following the sale, the insider directly owned 208,778 shares of the company's stock, valued at approximately $9,117,335.26. This represents a 4.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO James P. Mackin sold 12,500 shares of Artivion stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $42.32, for a total value of $529,000.00. Following the transaction, the chief executive officer owned 852,783 shares of the company's stock, valued at $36,089,776.56. The trade was a 1.44% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 97,790 shares of company stock valued at $3,634,659. Company insiders own 7.60% of the company's stock.

Artivion Stock Performance

Shares of NYSE AORT traded up $0.14 during mid-day trading on Thursday, hitting $43.88. The stock had a trading volume of 189,302 shares, compared to its average volume of 444,359. The company has a 50 day moving average of $34.51 and a two-hundred day moving average of $29.13. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78. The firm has a market cap of $2.07 billion, a PE ratio of -104.47 and a beta of 1.64. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $45.07.

Artivion (NYSE:AORT - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.24 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.13. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm had revenue of $112.97 million for the quarter, compared to analyst estimates of $107.96 million. The company's quarterly revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Research analysts predict that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.